Steve E Nissen
Overview
Explore the profile of Steve E Nissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desai M, Nissen S, Abraham T, Olivotto I, Garcia-Pavia P, Lopes R, et al.
JACC Heart Fail
. 2025 Feb;
13(2):358-370.
PMID: 39909647
There are no approved therapies for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The authors describe the baseline characteristics of ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy), a...
2.
Desai M, Nissen S
Am J Health Syst Pharm
. 2024 Oct;
PMID: 39450485
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted...
3.
Honda S, Puri R, Anderson T, Kastelein J, Brennan D, Kassahun H, et al.
JACC Cardiovasc Imaging
. 2021 Dec;
15(4):709-711.
PMID: 34922870
No abstract available.
4.
Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al.
JAMA Netw Open
. 2021 Feb;
4(2):e210369.
PMID: 33576820
Importance: There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression. Objective: To examine whether high-dose zinc and/or high-dose...
5.
Tower-Rader A, Ramchand J, Nissen S, Desai M
Expert Opin Investig Drugs
. 2020 Sep;
29(11):1171-1178.
PMID: 32897741
Introduction: Hypertrophic cardiomyopathy (HCM) is a common known monogenetic cardiovascular disorder which frequently leads to symptoms such as dyspnea and exercise intolerance. Current guideline-recommended pharmacotherapies have variable therapeutic responses. Mavacamten,...